24. November 2017

Instead of relying on organic market growth alone to propel revenue and profitability, what can CDMOs do differently? Could Big Pharma and CDMOs consider joint ownership or build and operate new business models? And, as globalisation affects the worldwide CDMO market, what are threats and opportunities, and how do CDMOs develop a sustainable business model in this landscape?